EXPANSION THERAPEUTICS
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
EXPANSION THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.expansionrx.com
Total Employee:
11+
Status:
Active
Contact:
(858) 764-4290
Email Addresses:
[email protected]
Total Funding:
135.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Domain Not Resolving Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Egle Therapeutics
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Lycia Therapeutics
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
QED Therapeutics
QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Siolta Therapeutics
Siolta Therapeutics is a biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
TenSixteen Bio
TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
5AM Ventures
5AM Ventures investment in Series B - Expansion Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - Expansion Therapeutics
Logos Capital
Logos Capital investment in Series B - Expansion Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Expansion Therapeutics
Kleiner Perkins
Kleiner Perkins investment in Series B - Expansion Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Expansion Therapeutics
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - Expansion Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Expansion Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Expansion Therapeutics
5AM Ventures
5AM Ventures investment in Series A - Expansion Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-01-24 | Expansion Therapeutics Names Sudhir Rao Senior Vice President of Business Development |
Official Site Inspections
http://www.expansionrx.com Semrush global rank: 4.98 M Semrush visits lastest month: 1.69 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Expansion Therapeutics"
LeadershipTeam - Expansionrx
We believe that the development of small molecule drugs that modulate RNA will dramatically change patient outcomes for diseases where treatment options for patients ...See details»
Expansion Therapeutics - Crunchbase Company Profile โฆ
Jan 4, 2018 Organization. Expansion Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Expansion Therapeutics is a biotechnology company focusing on โฆSee details»
Expansion Therapeutics - LinkedIn
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual ...See details»
Expansion Therapeutics Announces Key Additions and โฆ
Mar 2, 2023 Kenneth S. Kosik, M.D. โ Dr. Kosik is the Harriman Professor of Neuroscience Research and Co-Director of the Neuroscience Research Institute at the University of California, Santa Barbara. Previously, he was full professor โฆSee details»
Expansion Therapeutics Company Overview, Contact Details
Expansionrx hired Melissa A. Starovasnik as Scientific Advisory Board on Mar 2nd '23. Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral โฆSee details»
Expansion Therapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Expansion Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Working at Expansion Therapeutics - Zippia
Mar 14, 2024 www.expansionrx.com. Organization Type. Private. Social Media. Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of โฆSee details»
Expansion Therapeutics Announces Key Additions and Updates to ...
Mar 2, 2023 Prior to that, as Vice President, Research Operations and Structural Biology, she coordinated all operational activities for the more than 1300-member Genentech research โฆSee details»
Expansion Therapeutics Raises $80 Million Series B Financing to โฆ
Sep 29, 2021 Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated โฆSee details»
Expansion Therapeutics Raises $55.3 Million in Series A Financing โฆ
About Myotonic Dystrophy Type I Myotonic dystrophy type I (DM1) affects at least 1 in 8,000 people, or 40,000 individuals in the U.S. alone, and is the most frequent cause of adult onset โฆSee details»
Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., โฆ
Oct 26, 2022 Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today annoSee details»
Expansion Therapeutics Announces In-Licensing of Two New โฆ
May 25, 2021 For more information, visit www.expansionrx.com. About the Rainwater Charitable Foundation The Rainwater Charitable Foundation (RCF) was created in the early 1990s by โฆSee details»
Expansion Therapeutics Raises $80 Million Series B Financing to โฆ
Sep 29, 2021 Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the close โฆSee details»
Expansion Therapeutics Announces Key Additions and Updates to ...
Mar 2, 2023 --World-renowned scientists and clinicians will guide Expansionโs efforts to continue advancement of its small molecule RNA platform (SMIRNAโข) BOSTON--(BUSINESS WIRE)- โฆSee details»
PLATFORM - Expansionrx
We define druggable RNA structures by using knowledge of genetics and evolution We utilize proprietary tools and small molecule libraries, Chem-CLIP, NMR /docking /computational tools โฆSee details»
Expansion Therapeutics Raises $80 Million Series B Financing to โฆ
Sep 29, 2021 Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today annoSee details»
Expansion Therapeutics Names Mark Ledeboer, Ph.D., Senior Vice ...
Jun 14, 2021 Mark Ledeboer, Ph.D., Senior Vice President of Drug Discovery. โMark is a proven leader and drug hunter with more than 20 years of experience in the biotech industry and โฆSee details»
INSIGHTS - Expansionrx
-- Recognized industry leader brings deep scientific and operational experience to Expansion board. Boston, January 19, 2022 -- Expansion...See details»
Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board โฆ
Jan 19, 2022 Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today annoSee details»